Compare PVLA & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVLA | MFA |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 976.0M |
| IPO Year | N/A | N/A |
| Metric | PVLA | MFA |
|---|---|---|
| Price | $100.16 | $9.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $124.25 | $10.96 |
| AVG Volume (30 Days) | 258.4K | ★ 1.1M |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 14.98% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $279,011,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14.85 |
| P/E Ratio | ★ N/A | $11.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.17 | $7.85 |
| 52 Week High | $106.71 | $11.10 |
| Indicator | PVLA | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 63.90 | 60.19 |
| Support Level | $90.09 | $9.47 |
| Resistance Level | $106.71 | $9.70 |
| Average True Range (ATR) | 7.28 | 0.16 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 75.95 | 87.59 |
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.